Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSTORE phase 3 trial of rezafungin versus caspofungin for candidemia or invasive candidiasis
MOH_2019-03-10_006015Phase 3Recruiting
- Sponsor
- Cidara Therapeutics
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rezafungin, caspofungin and fluconazole in candidemia and invasive candidiasis (2 arms), sponsored by Cidara Therapeutics. Primary endpoint: Overall success at Day 14. Started Mar 2019; status: recruiting.
02
Drugs
rezafungincaspofunginfluconazole
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on MOH_2019-03-10_006015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-10_006015.